Literature DB >> 32304127

CD4+ T cells support polyfunctionality of cytotoxic CD8+ T cells with memory potential in immunological control of tumor.

Naoko Imai1,2, Isao Tawara3, Makiko Yamane1, Daisuke Muraoka1,4, Hiroshi Shiku1, Hiroaki Ikeda1,4.   

Abstract

Polyfunctionality/multifunctionality of effector T cells at the single cell level has been shown as an important parameter to predict the quality of T cell response and immunological control of infectious disease and malignancy. However, the fate of polyfunctional CD8+ CTLs and the factors that control the polyfunctionality of T cells remain largely unknown. Here we show that the acquisition of polyfunctionality on the initial stimulation is a sensitive immune correlate of CTL survival and memory formation. CD8+ T cells with high polyfunctionality, assessed with γ-interferon and tumor necrosis factor-α production and surface mobilization of the degranulation marker CD107a, showed enhanced Bcl-2 expression, low apoptosis, and increased CD127high KLRG1low memory precursor phenotype. Consistent with these observations, CD8+ T cells were found to acquire high frequency of cells with polyfunctionality when stimulated in conditions known to enhance memory formation, such as the presence of CD4+ T cells, interleukin (IL)-2, or IL-21. Utilizing T-cell receptor (TCR) transgenic mouse-derived CD8+ T cells that express a TCR specific for a tumor-derived neoantigen, we showed that polyfunctional tumor-specific CTLs generated in the presence of CD4+ T cells showed long persistence in vivo and induced enhanced tumor regression when adoptively transferred into mice with progressing tumor. Acquisition of polyfunctionality thus impacts CTL survival and memory formation associated with immunological control of tumor.
© 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Entities:  

Keywords:  CD4+ T cell; CTL; IL-2; cancer immunotherapy; polyfunctionality

Year:  2020        PMID: 32304127     DOI: 10.1111/cas.14420

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  7 in total

1.  NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome.

Authors:  Mikiya Ishihara; Shigehisa Kitano; Shinichi Kageyama; Yoshihiro Miyahara; Noboru Yamamoto; Hidefumi Kato; Hideyuki Mishima; Hiroyoshi Hattori; Takeru Funakoshi; Takashi Kojima; Tetsuro Sasada; Eiichi Sato; Sachiko Okamoto; Daisuke Tomura; Ikuei Nukaya; Hideto Chono; Junichi Mineno; Muhammad Faris Kairi; Phuong Diem Hoang Nguyen; Yannick Simoni; Alessandra Nardin; Evan Newell; Michael Fehlings; Hiroaki Ikeda; Takashi Watanabe; Hiroshi Shiku
Journal:  J Immunother Cancer       Date:  2022-06       Impact factor: 12.469

2.  Prognostic Value of Complement Component 2 and Its Correlation with Immune Infiltrates in Hepatocellular Carcinoma.

Authors:  Gang Ning; Yan-Lin Huang; Li-Min Zhen; Wen-Xiong Xu; Xue-Jun Li; Li-Na Wu; Ying Liu; Chan Xie; Liang Peng
Journal:  Biomed Res Int       Date:  2020-06-14       Impact factor: 3.411

3.  Infiltrating Immune Cells in Gastric Cancer: A Novel Predicting Model for Prognosis.

Authors:  Wenjie Li; Mengting Li; Haizhou Wang; Yanan Peng; Shouquan Dong; Yuanyuan Lu; Fan Wang; Fei Xu; Lan Liu; Qiu Zhao
Journal:  J Cancer       Date:  2021-01-01       Impact factor: 4.207

4.  CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers.

Authors:  Boris Duchemann; Marie Naigeon; Edouard Auclin; Roberto Ferrara; Lydie Cassard; Jean-Mehdi Jouniaux; Lisa Boselli; Jonathan Grivel; Aude Desnoyer; François-Xavier Danlos; Laura Mezquita; Caroline Caramella; Aurelien Marabelle; Benjamin Besse; Nathalie Chaput
Journal:  J Immunother Cancer       Date:  2022-02       Impact factor: 13.751

5.  The feasibility of proteomics sequencing based immune-related prognostic signature for predicting clinical outcomes of bladder cancer patients.

Authors:  Liren Jiang; Siteng Chen; Qi Pan; Jun Zheng; Jin He; Juanjuan Sun; Yaqin Han; Jiji Yang; Ning Zhang; Guohui Fu; Feng Gao
Journal:  BMC Cancer       Date:  2022-06-20       Impact factor: 4.638

6.  Edible Oxya chinensis sinuosa-Derived Protein as a Potential Nutraceutical for Anticancer Immunity Improvement.

Authors:  Woo Sik Kim; Jeong Moo Han; Ha-Yeon Song; Eui-Hong Byun; Ho Seong Seo; Eui-Baek Byun
Journal:  Nutrients       Date:  2020-10-22       Impact factor: 5.717

7.  CD4+ Memory Stem T Cell in Peripheral Blood: A Promising Immune Index for Early Screening and Auxiliary Diagnosis of Colorectal Cancer.

Authors:  Yan Lu; Qiaohong Zhang; Longyi Zhang
Journal:  Front Oncol       Date:  2021-07-13       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.